Related Experiment Video
Updated: Nov 27, 2025
11:22
Treatment of Osteochondral Defects in the Rabbit's Knee Joint by Implantation of Allogeneic Mesenchymal Stem Cells in Fibrin Clots
Published on: May 21, 2013
17.7K
Cell therapy for post-traumatic hip osteonecrosis in young patients
J Hernigou1, V Housset2, A Dubory2
1Department of Orthopaedic and Traumatology Surgery, EpiCURA hospital, Baudour/Hornu, Belgium.
Morphologie : Bulletin De L'Association Des Anatomistes
|December 2, 2020
Summary
Mesenchymal stem cell therapy shows promise for early-stage post-traumatic osteonecrosis of the femoral head, offering a viable alternative to hip arthroplasty with better long-term outcomes before collapse.
Area of Science:
- Orthopedics
- Regenerative Medicine
- Biotechnology
Background:
- Post-traumatic osteonecrosis of the femoral head (ONFH) is a debilitating condition often requiring surgical intervention.
- Current treatments for ONFH, such as hip arthroplasty, have limitations and associated revision rates.
- Mesenchymal stem cells (MSCs) offer a potential regenerative approach for treating ONFH.
Purpose of the Study:
- To evaluate the efficacy of mesenchymal stem cells (MSCs) injections for treating post-traumatic osteonecrosis of the femoral head (ONFH).
- To compare the outcomes of MSC therapy with traditional hip arthroplasty in patients with ONFH.
Main Methods:
- A prospective study involving 46 patients with ONFH, divided into two groups: 23 treated with MSC therapy and 23 with hip arthroplasty (control).
- Radiographic and clinical assessments (Harris Hip Score, visual analog scale) were performed over a minimum 10-year follow-up period.
- MSC therapy involved autologous bone marrow aspiration, concentration, and injection into the affected femoral head.
Main Results:
- The MSC therapy group demonstrated a significantly better survival time before requiring revision surgery (P<0.01).
- Early-stage ONFH (Stages I-II) treated with MSCs showed encouraging results, with a lower rate of collapse compared to controls.
- While 26% of MSC-treated hips eventually required total hip arthroplasty (THA), the control group had a 30.4% revision rate for primary THA.
Conclusions:
- Mesenchymal stem cell therapy presents encouraging outcomes for early-stage post-traumatic osteonecrosis of the femoral head.
- MSC therapy offers a potential alternative treatment option for early ONFH, potentially delaying or avoiding the need for hip arthroplasty.
- Further research is warranted to optimize MSC therapy protocols and long-term efficacy in ONFH management.
